Search - tctmd.com

Displaying 321 - 340 of 648

Sort: Relevancy | Date

Presentation TVT 2016

Tiara: Design Highlights and Clinical Update

Presenter: Martin B. Leon

June 16, 2016

Presentation TVT 2016

The Relentless Journey of TAVR to Lower-Risk Patients: Are We There Yet?

Presenter: Martin B. Leon

June 16, 2016

Presentation SOLACI 2016

Future Directions in TAVR: From Moderate-Low Risk Patients to New Devices

Presenter: Martin B. Leon

June 10, 2016

News Conference News ACC 2016

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

Yael L. Maxwell

April 03, 2016

News Conference News ACC 2016

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

Shelley Wood

April 02, 2016

News Features

Where Theory Meets Practice: Getting to the Heart of the Heart Team

Yael L. Maxwell

March 30, 2016

News Daily News

Patrick Whitlow, ‘Giant of Interventional Cardiology,’ Dies at 65

Yael L. Maxwell

March 22, 2016

Presentation JIM 2016

Meril LifeSciences MeRes: Design Specifications and Clinical Insights

Presenter: Martin B. Leon

February 10, 2016

Presentation JIM 2016

SAPIEN 3: Current Experience

Presenter: Martin B. Leon

February 09, 2016

Presentation TCT 2015

Meril Life Sciences MeRes: Differentiating Features and Clinical Update

Presenter: Alexandre Abizaid, Pieter C. Smits, Martin B. Leon

October 15, 2015

Presentation TCT 2015

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding Focused Commentary

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Martin W Bergmann

October 15, 2015

Presentation TCT 2015

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Brij Maini

October 15, 2015

Presentation TCT 2015

Severe Functional MR + Symptoms With Slightly Reduced LVEF (45%) and Moderate Surgical Risk: Treatment Options Focused Commentary

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Alec S. Vahanian

October 15, 2015

Presentation TCT 2015

Severe Functional MR + Symptoms With Slightly Reduced LVEF (45%) and Moderate Surgical Risk: Treatment Options

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Olaf Franzen

October 15, 2015

Presentation TCT 2015

Severe AS + Symptoms in an 80-Year-Old With Low Surgical Risk: TAVR or Surgery?

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Axel Linke

October 15, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

Presentation TCT 2015

An Update of New Aortic Valvuloplasty and Valve Remodeling Technologies

Presenter: Susheel Kodali, Axel Linke, Martin B. Leon

October 14, 2015

Presentation TCT 2015

Early Stage New TAVR Systems: Venus A Valve Technology Review and Clinical Update

Presenter: Martin B. Leon, Nicolo Piazza, Horst Sievert

October 14, 2015

Presentation TCT 2015

Early Stage New TAVR Systems: Valve Medical Technology Review and Clinical Update

Presenter: Martin B. Leon, Nicolo Piazza

October 14, 2015

Presentation TCT 2015

CE-Approved or EU Studies: ENGAGER Technology Review and Clinical Update

Presenter: Martin B. Leon, Nicolo Piazza, Hendrik Treede

October 14, 2015

Advertisement

Tiara: Design Highlights and Clinical Update

The Relentless Journey of TAVR to Lower-Risk Patients: Are We There Yet?

Future Directions in TAVR: From Moderate-Low Risk Patients to New Devices

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

Where Theory Meets Practice: Getting to the Heart of the Heart Team

Patrick Whitlow, ‘Giant of Interventional Cardiology,’ Dies at 65

Meril LifeSciences MeRes: Design Specifications and Clinical Insights

SAPIEN 3: Current Experience

Meril Life Sciences MeRes: Differentiating Features and Clinical Update

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding Focused Commentary

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding

Severe Functional MR + Symptoms With Slightly Reduced LVEF (45%) and Moderate Surgical Risk: Treatment Options Focused Commentary

Severe Functional MR + Symptoms With Slightly Reduced LVEF (45%) and Moderate Surgical Risk: Treatment Options

Severe AS + Symptoms in an 80-Year-Old With Low Surgical Risk: TAVR or Surgery?

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

An Update of New Aortic Valvuloplasty and Valve Remodeling Technologies

Early Stage New TAVR Systems: Venus A Valve Technology Review and Clinical Update

Early Stage New TAVR Systems: Valve Medical Technology Review and Clinical Update

CE-Approved or EU Studies: ENGAGER Technology Review and Clinical Update

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content